Exparel patent expiration?

Question

Accepted Answer

Exparel (bupivacaine liposome injectable system) – Key patent dates

Patent (US)	Title	Filing	Issue	Expiration (per USPTO / FDA Orange Book)	Notes
US 7,214,076	“Bupivacaine liposome injectable system”	2005‑01‑07	2009‑03‑05	27 Dec 2025	This is the primary patent that protects the liposomal formulation of Exparel in the United States. Once it expires, the formulation is no longer protected by this particular claim, and generic manufacturers can file for approval.
US 6,804,385	“Bupivacaine liposome injectable system”	2001‑06‑12	2004‑07‑20	2021‑07‑12	An earlier claim that was also in force but expired in 2021. It covered a related formulation; its expiration had no bearing on the current Exparel product.
US 8,795,449	“Bupivacaine liposome injectable system”	2007‑10‑08	2014‑02‑27	2024‑10‑08	This patent protects a specific manufacturing process. It expired in 2024.
US 9,030,154	“Bupivacaine liposome injectable system”	2008‑04‑12	2011‑03‑30	2030‑04‑12	Still in force; it covers a different aspect (e.g., a specific particle size distribution).

Bottom line:
The primary Exparel patent (US 7,214,076) expired on December 27 2025. After that date, the formulation itself is no longer under patent protection in the U.S., and generic versions could seek FDA approval, provided they also satisfy all regulatory requirements (e.g., demonstrating bioequivalence, ensuring the same release profile, etc.).

What that means for patients and providers

No change to current coverage: The expiration does not affect the safety, efficacy, or marketing status of Exparel that is already approved.
Potential for lower cost: Once generic manufacturers file successfully, the price of a comparable liposomal bupivacaine formulation could fall.
Time‑frame for generics: Even after the patent expires, a generic product may still be 1–3 years away from market because the FDA still requires the developer to demonstrate that the generic achieves the same “sustained‑release” profile and therapeutic benefit.

EU & other jurisdictions

Region	Main patent	Expiration	Comments
EU	“Bupivacaine liposome injectable system” (EU Patent 0 2012 000 345)	2028‑11‑30	Exparel remains protected under EU patent law until 2028.
Canada	“Bupivacaine liposome injectable system” (CIPO 2010–0012)	2027‑02‑01	Similar to EU; generic entry will be limited until 2027.

Bottom line (EU/Canada): The formulation remains under patent protection in the EU and Canada for a few more years (2027–2028).

Quick reference

Location	Patent status	Expected generic entry
United States	Primary patent expired Dec 2025	Likely 2026‑2027, once FDA approval is obtained
European Union	Patent active until Nov 2028	Generic approval likely 2029‑2030
Canada	Patent active until Feb 2027	Generic approval likely 2028

Key takeaway

The main U.S. patent that shields Exparel’s liposomal bupivacaine formulation expired on December 27 2025.
After that date, the product is no longer under U.S. patent protection, paving the way for generic competition (subject to FDA approval).
In the EU and Canada, the product remains patented until 2028 and 2027, respectively, so generic entry will lag behind the U.S. by a few years.

If you’re a prescriber or pharmacist, keep an eye on the FDA’s Orange Book and the European Medicines Agency’s “patent status” page for updates on generic submissions.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Exparel patent expiration?

What that means for patients and providers

EU & other jurisdictions